EN DE
Watch International Isotopes Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

International Isotopes Inc (INIS) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of International Isotopes Inc stock $0.03, price $0.04, that is 30.0% below the price, quality 36 out of 100. Rating: overvalued. Calculated from audited financials with 4 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

II International Isotopes Inc logo Thin data Nov 3, 2026

International Isotopes Inc

INIS · US
Expensive, weak quality

Our calculation puts a fair price 30% below what the stock costs today.

Low debt
Mixed Growth (revenue 5y +6.9 %/yr in USD)
Revenue last quarter 27% below a year ago.
Fair value $0.0280 · Overvalued
Quality 36/100
Loss-making · -25.5% net margin (TTM)
Negative free cash flow over the last twelve months
Trails peers (1/11)
Narrow moat 9/100
Thin data
Watch International Isotopes Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.1469 $0.0270 Fair Value $0.0280 Apr 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

60‑month range $0.0270 – $0.1469 · the $0.0400 price screens above the $0.0280 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.

Follow International Isotopes in your weekly email

Every Wednesday you see whether International Isotopes is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally.

Show moreShow less

It operates through five segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products.

The Theranostics Products segment produces and distributes Iodine-131 generic drug product and various isotopically pure radiochemicals for medical, industrial, and research applications.

The Cobalt Products segment produces cobalt-60 products and services, the fabrication of cobalt-60 sealed sources for radiation therapy, industrial and medical applications, and recycling of expended cobalt-60 sources.

The Calibration & Reference Products segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry.

This segment also offers flood sources, dose calibrators, cylinder phantoms, rod sources, line sources, flexible and rigid rulers, spot markers, pen point markers, and various specialty design items. The Medical Devices segment develops EasyFill Automated Capsule System, a robotic lab device.

The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility.

The company sells its products directly to end users and distributors. The company was formerly known as International Isotopes Inc. and changed its name to Radnostix, Inc. in December 2025. Radnostix, Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.

Stock analysis

International Isotopes Inc (INIS) currently trades at $0.0400, while our model-based Fair Value estimate is $0.0280, 30% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $0.0100 per share, and 0 of the 3 models we run sit above the $0.0400 price.

Bear case: the DCF Models group reads lowest at $0.0100, and 3 of the 3 models stay below the price. Data coverage for this calculation is low.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

International Isotopes Inc reported revenue of $13.1M in FY2025 versus $9.7M in FY2021, a compound +7.8%/yr. Reported net income was −$908K in FY2025.

Key figures

Market cap $21.1M Micro · P/S ratio 1.89 · Net margin −6.9% · Return on equity −93.0% · Return on assets (EBIT) −4.3% (5-year average) · Operating margin −31.2% · Revenue (TTM) $11.2M · Revenue growth (YoY) −26.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 60% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −30%, INIS screens richer than that median.

Fair Value models

Bear $0.0280 Fair Value $0.0280 Bull $0.0280
Price $0.0400 · Downside -30.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $0.0100 $0.0100 $0.0100 82
Growth DCF $0.0100 $0.0100 $0.0100 80
5Y Revenue Exit n/a n/a $0.0100 69
All 4 models by family
DCF Models
FCF DCF $0.0100 $0.0100 $0.0100 82
5Y Revenue Exit n/a n/a $0.0100 69
10Y Revenue Exit n/a $0.0100 $0.0100 65
Growth DCF
Growth DCF $0.0100 $0.0100 $0.0100 80

Open the full fair value analysis →

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 26
How much profit the company makes from its sales and capital
Quality Growth 6
Are margins and returns getting better?
Cashflow 16
Do the profits arrive as real cash?
Financial strength 31
Debt, balance sheet and risk of trouble
Investment 91
Does it invest with discipline instead of growing at any price?
Low Volatility 19
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 73
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 39/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−6.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.9%
Start year 2020 (pandemic). Over 10 years: +6.3% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−4.4% (2020) → −7.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+64.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +60.9% a year for the price.

INIS screens overvalued: fair value 30% below the price. Compare with Merck KGaA →

Compare International Isotopes Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 1/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Bottom 25%
Fair Value upside −30.0% · Below median
Profitability
Return on assets −5.1% · Bottom 25%
Net margin (12 months) −25.5% · Bottom 25%
Operating margin (12 months) −31.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −26.9% · Bottom 25%
Balance sheet
Debt / equity 0.48× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 5.72× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 1.88× · Cheaper than median
Price / free cash flow (fiscal year) 245.7× · Priciest 25%
PEG 5.59× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)76 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs INIS
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs INIS
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs INIS
Haleon plc HLN $9.14 $8.61 −6% vs INIS
Merck KGaA MRK €148.75 €109.18 −27% vs INIS
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs INIS
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs INIS
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs INIS
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs INIS
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs INIS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

International Isotopes Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "International Isotopes Inc Fair Value". https://www.fairvalue-calculator.com/stock/INIS

Frequently asked questions

Is International Isotopes Inc (INIS) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of $0.0280 versus a price of $0.0400, about 30% lower (overvalued).
What is the fair value of INIS?
Our model-based fair value for International Isotopes Inc is $0.0280 (as of Nov 3, 2026), built from audited fundamentals. The current price: $0.0400.
What is the quality score of INIS?
International Isotopes Inc has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for International Isotopes Inc (INIS)?
Our model-based price target is the fair value of $0.0280 (as of Nov 3, 2026) from 4 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the International Isotopes Inc stock forecast for 2026?
Our models put fair value at $0.0280, about 30% lower versus a price of $0.0400 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of International Isotopes Inc (INIS)?
International Isotopes Inc reported trailing-twelve-month revenue of about $11.2M (latest available figure, as of Nov 3, 2026).
What growth is priced into International Isotopes Inc (INIS)?
For today's price to be fair in a discounted-cash-flow model, International Isotopes Inc would have to grow free cash flow by +64.7 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.9 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of INIS use?
Our models discount International Isotopes Inc at 10.5 %: a base by market capitalisation (nano), damped by beta 1.32, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For International Isotopes Inc that is +64.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has International Isotopes Inc (INIS) delivered so far?
Over the past 5 years revenue at International Isotopes Inc grew +6.9 % a year. The price currently implies free-cash-flow growth of +64.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of International Isotopes Inc (INIS) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into International Isotopes Inc (+64.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of International Isotopes Inc (INIS)?
The free-cash-flow yield on the price is 0.41 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow International Isotopes Inc produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of International Isotopes Inc (INIS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For International Isotopes Inc it is $0.0280 per share (as of Nov 3, 2026), against a price of $0.0400. It is the blended result of 4 valuation models in 2 families (DCF Models, Growth DCF).
Is International Isotopes Inc stock overvalued or undervalued in 2026?
As of Nov 3, 2026, INIS trades above its calculated fair value: price $0.0400, fair value $0.0280, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INIS?
No. The price is what the market pays today ($0.0400); the fair value is what the company's own numbers justify ($0.0280). For International Isotopes Inc the two are $0.0120 per share apart. That gap is exactly why we show both numbers side by side.
How much is International Isotopes Inc worth?
The market values International Isotopes Inc at about $21.1M (market capitalisation, as of Nov 3, 2026). Per share that is $0.0400; our models calculate a fair value of $0.0280 per share.
What is the PEG ratio of INIS?
The PEG ratio of International Isotopes Inc is 5.59 (P/E divided by earnings growth, as of Nov 3, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of International Isotopes Inc (INIS)?
Balance-sheet figures for International Isotopes Inc (as of Nov 3, 2026): return on equity −93.0%, debt of 0.48 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is INIS from its 52-week high?
International Isotopes Inc trades at $0.0400, about 60% below its 52-week high of $0.1000 and 5% above the low of $0.0380 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0280 is for.
Which stocks are comparable to International Isotopes Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is International Isotopes Inc stock attractive at the current price?
The data as of Nov 3, 2026: price $0.0400, calculated fair value $0.0280 (−30%), Quality Score 36/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INIS calculated?
We run International Isotopes Inc through 4 models from 2 families: DCF Models, Growth DCF. Every model gets the same audited fundamentals; the fair value of $0.0280 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. International Isotopes Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of International Isotopes Inc (INIS)?
The closing price on Nov 6, 2026 was $0.0400. Our model-based fair value is $0.0280, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with International Isotopes Inc right now?
The price sits above even our optimistic bull case ($0.0280). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of International Isotopes Inc

How large is the market capitalisation of International Isotopes Inc (INIS)?
The market capitalisation of International Isotopes Inc is $21.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of International Isotopes Inc (INIS)?
The price-to-sales ratio of International Isotopes Inc is 1.89 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of International Isotopes Inc (INIS)?
The net margin of International Isotopes Inc is −6.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of International Isotopes Inc (INIS)?
The return on equity (ROE) of International Isotopes Inc is −93.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of International Isotopes Inc (INIS)?
On an EBIT basis the return on assets of International Isotopes Inc is −4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of International Isotopes Inc (INIS)?
The operating margin of International Isotopes Inc is −31.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at International Isotopes Inc (INIS)?
Revenue at International Isotopes Inc is growing −26.9% versus a year earlier (3y avg +5.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does International Isotopes Inc (INIS) carry?
The net debt of International Isotopes Inc is $237K (fiscal year 2025, ≈ 2.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch International Isotopes Inc in the live analysis

One click puts International Isotopes Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.